Reproducible Biphasic Cutaneous Edema Induced by Topical and Repeated Application of Antigen in Sensitized Mice

An allergic dermatitis model was developed by repeated sensitization and challenge with antigen (ovalbumin, OA) over 7 months in mice. ddY mice were sensitized by i.p. injection of OA adsorbed in Al(OH)3 (1 μg OA/2 mg Al(OH)3/animal one every 3 weeks. Antigen challenge was conducted by injection of...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Biological & pharmaceutical bulletin 2000/04/01, Vol.23(4), pp.432-437
Hauptverfasser: MIYAKE, Isao, NABE, Takeshi, YAMAMURA, Hideki, KOHNO, Shigekatsu
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 437
container_issue 4
container_start_page 432
container_title Biological & pharmaceutical bulletin
container_volume 23
creator MIYAKE, Isao
NABE, Takeshi
YAMAMURA, Hideki
KOHNO, Shigekatsu
description An allergic dermatitis model was developed by repeated sensitization and challenge with antigen (ovalbumin, OA) over 7 months in mice. ddY mice were sensitized by i.p. injection of OA adsorbed in Al(OH)3 (1 μg OA/2 mg Al(OH)3/animal one every 3 weeks. Antigen challenge was conducted by injection of OA solution (0.1, 1 and 10 μg/site) into the skin of the hind paw instep 10 d after the respective sensitizations. At the 1st challenge, all the 3 groups showed an immediate edematous response with the peak at 30 min or 1 h after the challenge. The group challenged with the highest dose (10 μg/site) of the antigen developed a clear late-phase edema, which was observed at the 2nd challenge, increasing until the 3rd challenge, reaching a plateau at further challenges. On the other hand, such late phase edema scarcely developed in the group challenged with the lowest dose (0.1 μg/site) of the antigen. The amount of circulating specific IgE antibody increased following repeated sensitizations and challenges in all groups, but there were no significant differences in the levels among them. Mepyramine suppressed the early edema by approximately 50%, yet the late phase edema was unaffected. In conclusion, using Al(OH)3+antigen for sensitization and an appropriate amount of antigen for challenge, reproducible biphasic edematous responses were observed long-term without desensitization. This model may by classified as an acute allergic dermatitis and can be useful for quantitatively evaluating the effects of anti-allergic drugs.
doi_str_mv 10.1248/bpb.23.432
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71072892</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3120456541</sourcerecordid><originalsourceid>FETCH-LOGICAL-c587t-4b1ba331b66100e6c7635fa80a876505a06d5cbbada9c175b5d02a8c5cff092f3</originalsourceid><addsrcrecordid>eNpdkU9v1DAQxS1ERbeFCx8AWQL1gJTFfxPnuKwKVGqFBOVsjR2n9SrrBNs5lE-Pl6xK1Ystzfw8z_MeQm8pWVMm1CczmTXja8HZC7SiXDSVZFS-RCvSUlXVVKpTdJbSjhDSEMZfoVNKGiUEYys0_nBTHLvZejM4_NlP95C8xds5Q3DjnPBl5_aAr0JBXIfNA74dJ29hwBA6XB47yKW-maahVLMfAx57vAnZ37mAfcA_XUg--z8FuvHWvUYnPQzJvTne5-jXl8vb7bfq-vvXq-3murJSNbkShhrgnJq6poS42jY1lz0oAqqpJZFA6k5aY6CD1tJGGtkRBspK2_ekZT0_RxfL3LLd79mlrPc-WTcMy1q6KRYw1bICvn8G7sY5hvI3TYUoBjZMHKiPC2XjmFJ0vZ6i30N80JToQwi6hKAZ1yWEAr87jpzN3nVP0MX1Anw4ApCKlX2EYH36z3EpqZAF2y7YLmW4c499iNnbwR0kadvyf7LLUdQfu_YeonaB_wXC0qZr</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1449187242</pqid></control><display><type>article</type><title>Reproducible Biphasic Cutaneous Edema Induced by Topical and Repeated Application of Antigen in Sensitized Mice</title><source>J-STAGE Free</source><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Free Full-Text Journals in Chemistry</source><creator>MIYAKE, Isao ; NABE, Takeshi ; YAMAMURA, Hideki ; KOHNO, Shigekatsu</creator><creatorcontrib>MIYAKE, Isao ; NABE, Takeshi ; YAMAMURA, Hideki ; KOHNO, Shigekatsu</creatorcontrib><description>An allergic dermatitis model was developed by repeated sensitization and challenge with antigen (ovalbumin, OA) over 7 months in mice. ddY mice were sensitized by i.p. injection of OA adsorbed in Al(OH)3 (1 μg OA/2 mg Al(OH)3/animal one every 3 weeks. Antigen challenge was conducted by injection of OA solution (0.1, 1 and 10 μg/site) into the skin of the hind paw instep 10 d after the respective sensitizations. At the 1st challenge, all the 3 groups showed an immediate edematous response with the peak at 30 min or 1 h after the challenge. The group challenged with the highest dose (10 μg/site) of the antigen developed a clear late-phase edema, which was observed at the 2nd challenge, increasing until the 3rd challenge, reaching a plateau at further challenges. On the other hand, such late phase edema scarcely developed in the group challenged with the lowest dose (0.1 μg/site) of the antigen. The amount of circulating specific IgE antibody increased following repeated sensitizations and challenges in all groups, but there were no significant differences in the levels among them. Mepyramine suppressed the early edema by approximately 50%, yet the late phase edema was unaffected. In conclusion, using Al(OH)3+antigen for sensitization and an appropriate amount of antigen for challenge, reproducible biphasic edematous responses were observed long-term without desensitization. This model may by classified as an acute allergic dermatitis and can be useful for quantitatively evaluating the effects of anti-allergic drugs.</description><identifier>ISSN: 0918-6158</identifier><identifier>EISSN: 1347-5215</identifier><identifier>DOI: 10.1248/bpb.23.432</identifier><identifier>PMID: 10784422</identifier><language>eng</language><publisher>Tokyo: The Pharmaceutical Society of Japan</publisher><subject>allergic dermatitis ; Allergic diseases ; Animals ; Antigens - administration &amp; dosage ; Benzoquinones - therapeutic use ; Biological and medical sciences ; Cyclooxygenase Inhibitors - therapeutic use ; Dermatitis, Allergic Contact - drug therapy ; Dermatitis, Allergic Contact - etiology ; histamine ; Histamine and antagonists. Allergy ; Histamine H1 Antagonists - therapeutic use ; IgE ; Immunopathology ; Indomethacin - therapeutic use ; Lipoxygenase Inhibitors - therapeutic use ; Male ; Medical sciences ; Mice ; Ovalbumin - administration &amp; dosage ; paw edema ; Pharmacology. Drug treatments ; Pyrilamine - therapeutic use ; Reproducibility of Results ; Skin allergic diseases. Stinging insect allergies</subject><ispartof>Biological and Pharmaceutical Bulletin, 2000/04/01, Vol.23(4), pp.432-437</ispartof><rights>The Pharmaceutical Society of Japan</rights><rights>2000 INIST-CNRS</rights><rights>Copyright Japan Science and Technology Agency 2000</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,1883,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=1355145$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10784422$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>MIYAKE, Isao</creatorcontrib><creatorcontrib>NABE, Takeshi</creatorcontrib><creatorcontrib>YAMAMURA, Hideki</creatorcontrib><creatorcontrib>KOHNO, Shigekatsu</creatorcontrib><title>Reproducible Biphasic Cutaneous Edema Induced by Topical and Repeated Application of Antigen in Sensitized Mice</title><title>Biological &amp; pharmaceutical bulletin</title><addtitle>Biol Pharm Bull</addtitle><description>An allergic dermatitis model was developed by repeated sensitization and challenge with antigen (ovalbumin, OA) over 7 months in mice. ddY mice were sensitized by i.p. injection of OA adsorbed in Al(OH)3 (1 μg OA/2 mg Al(OH)3/animal one every 3 weeks. Antigen challenge was conducted by injection of OA solution (0.1, 1 and 10 μg/site) into the skin of the hind paw instep 10 d after the respective sensitizations. At the 1st challenge, all the 3 groups showed an immediate edematous response with the peak at 30 min or 1 h after the challenge. The group challenged with the highest dose (10 μg/site) of the antigen developed a clear late-phase edema, which was observed at the 2nd challenge, increasing until the 3rd challenge, reaching a plateau at further challenges. On the other hand, such late phase edema scarcely developed in the group challenged with the lowest dose (0.1 μg/site) of the antigen. The amount of circulating specific IgE antibody increased following repeated sensitizations and challenges in all groups, but there were no significant differences in the levels among them. Mepyramine suppressed the early edema by approximately 50%, yet the late phase edema was unaffected. In conclusion, using Al(OH)3+antigen for sensitization and an appropriate amount of antigen for challenge, reproducible biphasic edematous responses were observed long-term without desensitization. This model may by classified as an acute allergic dermatitis and can be useful for quantitatively evaluating the effects of anti-allergic drugs.</description><subject>allergic dermatitis</subject><subject>Allergic diseases</subject><subject>Animals</subject><subject>Antigens - administration &amp; dosage</subject><subject>Benzoquinones - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Cyclooxygenase Inhibitors - therapeutic use</subject><subject>Dermatitis, Allergic Contact - drug therapy</subject><subject>Dermatitis, Allergic Contact - etiology</subject><subject>histamine</subject><subject>Histamine and antagonists. Allergy</subject><subject>Histamine H1 Antagonists - therapeutic use</subject><subject>IgE</subject><subject>Immunopathology</subject><subject>Indomethacin - therapeutic use</subject><subject>Lipoxygenase Inhibitors - therapeutic use</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Ovalbumin - administration &amp; dosage</subject><subject>paw edema</subject><subject>Pharmacology. Drug treatments</subject><subject>Pyrilamine - therapeutic use</subject><subject>Reproducibility of Results</subject><subject>Skin allergic diseases. Stinging insect allergies</subject><issn>0918-6158</issn><issn>1347-5215</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkU9v1DAQxS1ERbeFCx8AWQL1gJTFfxPnuKwKVGqFBOVsjR2n9SrrBNs5lE-Pl6xK1Ystzfw8z_MeQm8pWVMm1CczmTXja8HZC7SiXDSVZFS-RCvSUlXVVKpTdJbSjhDSEMZfoVNKGiUEYys0_nBTHLvZejM4_NlP95C8xds5Q3DjnPBl5_aAr0JBXIfNA74dJ29hwBA6XB47yKW-maahVLMfAx57vAnZ37mAfcA_XUg--z8FuvHWvUYnPQzJvTne5-jXl8vb7bfq-vvXq-3murJSNbkShhrgnJq6poS42jY1lz0oAqqpJZFA6k5aY6CD1tJGGtkRBspK2_ekZT0_RxfL3LLd79mlrPc-WTcMy1q6KRYw1bICvn8G7sY5hvI3TYUoBjZMHKiPC2XjmFJ0vZ6i30N80JToQwi6hKAZ1yWEAr87jpzN3nVP0MX1Anw4ApCKlX2EYH36z3EpqZAF2y7YLmW4c499iNnbwR0kadvyf7LLUdQfu_YeonaB_wXC0qZr</recordid><startdate>20000401</startdate><enddate>20000401</enddate><creator>MIYAKE, Isao</creator><creator>NABE, Takeshi</creator><creator>YAMAMURA, Hideki</creator><creator>KOHNO, Shigekatsu</creator><general>The Pharmaceutical Society of Japan</general><general>Maruzen</general><general>Japan Science and Technology Agency</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7QR</scope><scope>7TK</scope><scope>7U9</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20000401</creationdate><title>Reproducible Biphasic Cutaneous Edema Induced by Topical and Repeated Application of Antigen in Sensitized Mice</title><author>MIYAKE, Isao ; NABE, Takeshi ; YAMAMURA, Hideki ; KOHNO, Shigekatsu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c587t-4b1ba331b66100e6c7635fa80a876505a06d5cbbada9c175b5d02a8c5cff092f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>allergic dermatitis</topic><topic>Allergic diseases</topic><topic>Animals</topic><topic>Antigens - administration &amp; dosage</topic><topic>Benzoquinones - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Cyclooxygenase Inhibitors - therapeutic use</topic><topic>Dermatitis, Allergic Contact - drug therapy</topic><topic>Dermatitis, Allergic Contact - etiology</topic><topic>histamine</topic><topic>Histamine and antagonists. Allergy</topic><topic>Histamine H1 Antagonists - therapeutic use</topic><topic>IgE</topic><topic>Immunopathology</topic><topic>Indomethacin - therapeutic use</topic><topic>Lipoxygenase Inhibitors - therapeutic use</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Ovalbumin - administration &amp; dosage</topic><topic>paw edema</topic><topic>Pharmacology. Drug treatments</topic><topic>Pyrilamine - therapeutic use</topic><topic>Reproducibility of Results</topic><topic>Skin allergic diseases. Stinging insect allergies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>MIYAKE, Isao</creatorcontrib><creatorcontrib>NABE, Takeshi</creatorcontrib><creatorcontrib>YAMAMURA, Hideki</creatorcontrib><creatorcontrib>KOHNO, Shigekatsu</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Biological &amp; pharmaceutical bulletin</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>MIYAKE, Isao</au><au>NABE, Takeshi</au><au>YAMAMURA, Hideki</au><au>KOHNO, Shigekatsu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Reproducible Biphasic Cutaneous Edema Induced by Topical and Repeated Application of Antigen in Sensitized Mice</atitle><jtitle>Biological &amp; pharmaceutical bulletin</jtitle><addtitle>Biol Pharm Bull</addtitle><date>2000-04-01</date><risdate>2000</risdate><volume>23</volume><issue>4</issue><spage>432</spage><epage>437</epage><pages>432-437</pages><issn>0918-6158</issn><eissn>1347-5215</eissn><abstract>An allergic dermatitis model was developed by repeated sensitization and challenge with antigen (ovalbumin, OA) over 7 months in mice. ddY mice were sensitized by i.p. injection of OA adsorbed in Al(OH)3 (1 μg OA/2 mg Al(OH)3/animal one every 3 weeks. Antigen challenge was conducted by injection of OA solution (0.1, 1 and 10 μg/site) into the skin of the hind paw instep 10 d after the respective sensitizations. At the 1st challenge, all the 3 groups showed an immediate edematous response with the peak at 30 min or 1 h after the challenge. The group challenged with the highest dose (10 μg/site) of the antigen developed a clear late-phase edema, which was observed at the 2nd challenge, increasing until the 3rd challenge, reaching a plateau at further challenges. On the other hand, such late phase edema scarcely developed in the group challenged with the lowest dose (0.1 μg/site) of the antigen. The amount of circulating specific IgE antibody increased following repeated sensitizations and challenges in all groups, but there were no significant differences in the levels among them. Mepyramine suppressed the early edema by approximately 50%, yet the late phase edema was unaffected. In conclusion, using Al(OH)3+antigen for sensitization and an appropriate amount of antigen for challenge, reproducible biphasic edematous responses were observed long-term without desensitization. This model may by classified as an acute allergic dermatitis and can be useful for quantitatively evaluating the effects of anti-allergic drugs.</abstract><cop>Tokyo</cop><pub>The Pharmaceutical Society of Japan</pub><pmid>10784422</pmid><doi>10.1248/bpb.23.432</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0918-6158
ispartof Biological and Pharmaceutical Bulletin, 2000/04/01, Vol.23(4), pp.432-437
issn 0918-6158
1347-5215
language eng
recordid cdi_proquest_miscellaneous_71072892
source J-STAGE Free; MEDLINE; EZB-FREE-00999 freely available EZB journals; Free Full-Text Journals in Chemistry
subjects allergic dermatitis
Allergic diseases
Animals
Antigens - administration & dosage
Benzoquinones - therapeutic use
Biological and medical sciences
Cyclooxygenase Inhibitors - therapeutic use
Dermatitis, Allergic Contact - drug therapy
Dermatitis, Allergic Contact - etiology
histamine
Histamine and antagonists. Allergy
Histamine H1 Antagonists - therapeutic use
IgE
Immunopathology
Indomethacin - therapeutic use
Lipoxygenase Inhibitors - therapeutic use
Male
Medical sciences
Mice
Ovalbumin - administration & dosage
paw edema
Pharmacology. Drug treatments
Pyrilamine - therapeutic use
Reproducibility of Results
Skin allergic diseases. Stinging insect allergies
title Reproducible Biphasic Cutaneous Edema Induced by Topical and Repeated Application of Antigen in Sensitized Mice
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T13%3A50%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Reproducible%20Biphasic%20Cutaneous%20Edema%20Induced%20by%20Topical%20and%20Repeated%20Application%20of%20Antigen%20in%20Sensitized%20Mice&rft.jtitle=Biological%20&%20pharmaceutical%20bulletin&rft.au=MIYAKE,%20Isao&rft.date=2000-04-01&rft.volume=23&rft.issue=4&rft.spage=432&rft.epage=437&rft.pages=432-437&rft.issn=0918-6158&rft.eissn=1347-5215&rft_id=info:doi/10.1248/bpb.23.432&rft_dat=%3Cproquest_cross%3E3120456541%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1449187242&rft_id=info:pmid/10784422&rfr_iscdi=true